MEI Pharma Inc (MEIP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, MEI Pharma Inc (MEIP) has a cash flow conversion efficiency ratio of -0.145x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.46 Million) by net assets ($16.93 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see MEI Pharma Inc market cap and net worth for the company's overall valuation and market capitalisation.
MEI Pharma Inc - Cash Flow Conversion Efficiency Trend (2003–2025)
This chart illustrates how MEI Pharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
MEI Pharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of MEI Pharma Inc ranked by their cash flow conversion efficiency. Explore cash flow quality index of MEI Pharma Inc to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CLERHP Estructuras S.A
MC:CLR
|
-0.061x |
|
Vranken-Pommery Monopole Société Anonyme
PA:VRAP
|
-0.107x |
|
Y.C.C. Parts MFG Co Ltd
TW:1339
|
0.041x |
|
Mitake Information
TWO:8284
|
-0.013x |
|
Easy Field
TWO:6425
|
-0.018x |
|
Suria Capital Holdings Bhd
KLSE:6521
|
-0.009x |
|
Wonder Electricals Limited
NSE:WEL
|
0.133x |
|
Source Energy Services Ltd
TO:SHLE
|
0.166x |
Annual Cash Flow Conversion Efficiency for MEI Pharma Inc (2003–2025)
The table below shows the annual cash flow conversion efficiency of MEI Pharma Inc from 2003 to 2025. View latest MEI Pharma Inc stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $16.93 Million | $-20.84 Million | -1.231x | +19.46% |
| 2024-06-30 | $33.02 Million | $-50.47 Million | -1.529x | +28.28% |
| 2023-06-30 | $24.62 Million | $-52.48 Million | -2.131x | -129.18% |
| 2022-06-30 | $52.41 Million | $-48.75 Million | -0.930x | -20.35% |
| 2021-06-30 | $41.36 Million | $-31.96 Million | -0.773x | -276.44% |
| 2020-06-30 | $78.22 Million | $34.26 Million | 0.438x | +171.35% |
| 2019-06-30 | $47.93 Million | $-29.42 Million | -0.614x | -45.41% |
| 2018-06-30 | $50.46 Million | $-21.30 Million | -0.422x | -715.66% |
| 2017-06-30 | $50.84 Million | $3.49 Million | 0.069x | +115.99% |
| 2016-06-30 | $41.65 Million | $-17.86 Million | -0.429x | +8.68% |
| 2015-06-30 | $59.79 Million | $-28.07 Million | -0.469x | -9.07% |
| 2014-06-30 | $45.19 Million | $-19.45 Million | -0.430x | -49.43% |
| 2013-06-30 | $34.87 Million | $-10.04 Million | -0.288x | +81.29% |
| 2012-06-30 | $4.60 Million | $-7.08 Million | -1.540x | +57.51% |
| 2011-06-30 | $1.79 Million | $-6.50 Million | -3.624x | -166.59% |
| 2010-06-30 | $7.38 Million | $-10.03 Million | -1.359x | -95.94% |
| 2009-06-30 | $15.21 Million | $-10.55 Million | -0.694x | +0.23% |
| 2008-06-30 | $16.54 Million | $-11.50 Million | -0.695x | +11.18% |
| 2007-06-30 | $13.78 Million | $-10.79 Million | -0.783x | +21.31% |
| 2006-06-30 | $9.13 Million | $-9.09 Million | -0.995x | -194.53% |
| 2005-06-30 | $16.52 Million | $-5.58 Million | -0.338x | +2.78% |
| 2004-06-30 | $22.94 Million | $-7.97 Million | -0.347x | -11.98% |
| 2003-06-30 | $5.93 Million | $-1.84 Million | -0.310x | -- |
About MEI Pharma Inc
MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. It develops ME-344, an intravenous small molecule inhibitor mitochondrial oxidative phosphorylation to treat human epidermal growth factor receptor 2 negative breast cancer, colorectal cancer, and solid tumors. The company was formerly known as Marshall Edwards, … Read more